Header cover image

Dutch (AEX) Biotech Industry Analysis

UpdatedMay 28, 2024
DataAggregated Company Financials
Companies3
  • 7D-1.1%
  • 3M-26.5%
  • 1Y-39.3%
  • YTD-31.0%

Over the last 7 days, the Biotech industry has dropped 2.2%, driven by Galapagos declining 2.8%. On the other hand Vivoryon Therapeutics is actually up 9.2%. The industry has fallen 40% in the last year. In the next few years, earnings are forecast to decline by 19% annually.

Industry Valuation and Performance

Has the Dutch Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 29 May 2024€2.2b€481.5m€20.8m54.2x107x4.6x
Fri, 26 Apr 2024€2.3b€468.4m-€13,820,845.60n/a-169.6x5x
Sun, 24 Mar 2024€2.7b€466.7m-€39,641,122.60n/a-68.6x5.8x
Tue, 20 Feb 2024€3.4b€746.9m-€199,818,423.50n/a-16.8x4.5x
Thu, 18 Jan 2024€3.3b€745.0m-€199,626,545.00n/a-16.5x4.4x
Sat, 16 Dec 2023€3.3b€744.6m-€199,589,052.00n/a-16.6x4.5x
Mon, 13 Nov 2023€3.1b€748.7m-€199,999,275.00n/a-15.6x4.2x
Wed, 11 Oct 2023€3.2b€754.7m-€199,116,174.00n/a-16.3x4.3x
Fri, 08 Sep 2023€3.3b€752.9m-€200,841,979.00n/a-16.6x4.4x
Sun, 06 Aug 2023€3.7b€747.6m-€200,420,037.00n/a-18.3x4.9x
Tue, 04 Jul 2023€3.5b€732.3m-€211,456,423.00n/a-16.5x4.8x
Thu, 01 Jun 2023€3.6b€736.9m-€211,502,108.00n/a-17.3x5x
Sat, 29 Apr 2023€3.3b€691.6m-€233,759,723.0054.2x-14.2x4.8x
Mon, 27 Mar 2023€3.3b€707.1m-€218,849,384.0051.1x-14.9x4.6x
Wed, 22 Feb 2023€3.5b€779.0m€20.5m227.6x169.4x4.5x
Fri, 20 Jan 2023€4.0b€776.5m€20.1m268.5x199.6x5.2x
Sun, 18 Dec 2022€3.5b€780.1m€20.6m237.4x167.8x4.4x
Tue, 15 Nov 2022€3.6b€785.1m€21.4m252.1x167.9x4.6x
Thu, 13 Oct 2022€3.7b€724.5m-€72,678,912.0029.5x-50.9x5.1x
Sat, 10 Sep 2022€4.1b€717.5m-€72,492,388.0038.8x-56.8x5.7x
Mon, 08 Aug 2022€4.3b€715.2m-€72,651,044.0028.5x-58.6x6x
Wed, 06 Jul 2022€4.3b€715.2m-€127,884,323.0046.2x-33.3x6x
Fri, 03 Jun 2022€4.1b€707.6m-€128,293,254.0048.1x-31.7x5.7x
Sun, 01 May 2022€4.4b€684.3m-€121,808,396.0033.8x-36.1x6.4x
Tue, 29 Mar 2022€4.5b€663.3m-€123,499,000.0037.1x-36.3x6.8x
Thu, 24 Feb 2022€4.5b€709.9m-€193,509,000.0026.4x-23.3x6.4x
Sat, 22 Jan 2022€4.1b€709.9m-€193,509,000.0027.1x-21.3x5.8x
Mon, 20 Dec 2021€4.0b€709.9m-€193,509,000.0025.2x-20.5x5.6x
Wed, 17 Nov 2021€3.9b€709.9m-€193,509,000.0027.1x-20.4x5.5x
Fri, 15 Oct 2021€4.0b€764.7m-€212,734,000.0019.5x-18.7x5.2x
Sun, 12 Sep 2021€4.2b€778.3m-€227,353,000.0020.5x-18.4x5.4x
Tue, 10 Aug 2021€4.3b€764.7m-€208,635,000.0021.6x-20.5x5.6x
Price to Earnings Ratio

-19.2x


Total Market Cap: €4.9bTotal Earnings: -€256,424,000.00Total Revenue: €723.3mTotal Market Cap vs Earnings and Revenue0%0%0%
Dutch Biotech Industry Price to Earnings3Y Average -4.9x202220232024
Current Industry PE
    There are only 3 companies in the Dutch Biotechs industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.
Past Earnings Growth
  • Total earnings for the Biotechs industry have gone up over the last three years and the industry is now profitable.
  • Revenues have declined 13% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, profits have been increasing.

Industry Trends

Which industries have driven the changes within the Dutch Healthcare industry?

NL Market0.17%
Healthcare-1.60%
Biotech-1.11%
Biotech-1.11%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VVY Vivoryon Therapeutics€2.88260.0%
+€54.2m
-80.4%PB2.9x
PHARM Pharming Group€0.843.7%
+€20.2m
-26.6%PS2.4x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.